Thomas A. Satterfield, Jr. filed Amendment No. 4 to a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 1,539,134 shares of BioCardia, Inc. common stock, representing 9.9% of the company's outstanding shares as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Thomas A. Satterfield, Jr. reported beneficial ownership of 1,539,134 shares of BioCardia, Inc. common stock, representing 9.9% of shares outstanding.
  • Shares outstanding basis: The percentage was calculated using 15,138,782 shares outstanding as of August 11, 2026, as reported by the issuer in its quarterly report for the fiscal quarter ended June 30, 2026.
  • Warrant holdings subject to blocker: Satterfield holds 1,040,349 warrants, each to purchase one share of common stock, all subject to a blocker provision capping beneficial ownership at 9.99%.
  • Uncapped potential ownership: Without the blocker provision, Satterfield could be deemed to beneficially own 2,311,514 shares, representing 14.29% of outstanding common stock.
  • Voting power split: Satterfield reported sole voting power over 234,604 shares and shared voting power over 1,304,530 shares.
  • Holdings held through affiliated entities: Shares are held directly and through Tomsat Investment and Trading Co., Inc., A.G. Family L.P., and Caldwell Mill Opportunity Fund, LLC, among others.

Satterfield's BioCardia Ownership Structure and Warrant Blocker Details

According to the filing, Thomas A. Satterfield, Jr., a United States citizen residing in Gulf Breeze, Florida, holds his beneficial interest in BioCardia, Inc. (NASDAQ:BCDA) through a combination of directly and indirectly owned shares and warrants. BioCardia, Inc. is a clinical-stage cardiovascular biotherapeutics company headquartered at 320 Soquel Way, Sunnyvale, CA 94085. The 1,539,134 shares reported as beneficially owned consist of 1,271,165 shares of common stock and 267,969 shares issuable upon warrant exercise, which the filing states represent "the Reporting Person's maximum beneficial ownership permissible under the applicable blocker provisions, or 9.99%."

The filing discloses that Satterfield's holdings are spread across several affiliated entities and accounts. According to the Schedule 13G, Tomsat Investment and Trading Co., Inc., a corporation wholly owned by Satterfield and of which he serves as President, holds 319,976 shares of common stock and warrants covering 405,175 shares. A.G. Family L.P., a partnership managed by a general partner controlled by Satterfield, holds 350,847 shares of common stock and warrants covering 575,912 shares. Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity in which Satterfield holds a 50% interest and serves as Chief Investment Manager, holds 400,000 shares of common stock. Additionally, Satterfield holds a limited power of attorney for voting and disposition over 25,000 shares held by Rebecca A. Satterfield, who, according to the filing, retains the right to receive proceeds from any sale of those shares.

The filing notes that due to field limitations of the EDGAR filing system, the percentage in Row 11 was rounded down to 9.9%, though the actual threshold governing the blocker provision is 9.99%. All 1,040,349 warrants are subject to the blocker, and the filing specifies that 59,262 of those warrants, designated "Sole Power Warrants," would upon exercise result in shares over which Satterfield would have sole voting and dispositive power.

What Was Disclosed

Thomas A. Satterfield, Jr. filed Amendment No. 4 to Schedule 13G reporting 1,539,134 shares of BioCardia, Inc. common stock beneficially owned as of September 30, 2026, equal to 9.9% of shares outstanding, with holdings distributed across multiple affiliated entities and subject to warrant blocker provisions.